Competitor Analysis ErbB / Her Receptor Antagonists

Publisher: La Merie Publishing
Pages: 168
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0130
Release Date: July of 2013

650.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis ErbB / Her Receptor Antagonists

Product description

The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody  therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.

The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis ErbB / Her Receptor Antagonists

Table of Contents

  • Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
  • Sales of Antibodies Targeting ErbB/Her Receptors

1) Small Molecules Targeting the ErbB/Her Receptor Family
a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors
- Tarceva Pipeline
- Iressa Pipeline
- Pipeline of Other EGF-R Selective TK Inhibitors
b) Selective Her2 (ErbB2) TK Inhibitors
c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
- Tykerb  Pipeline
- Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors
- Gilotrif Pipeline
- Neratinib Pipeline
- Dacomitinb Pipeline
- Poziotinib Pipeline
- Pipeline of Other Pan-Her Tk Inhibitors
e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition
f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition

2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family

3) Vaccines Targeting the ErbB/Her Receptor Family
a) EGF-R (ErbB1) Vaccines
b) Her2 (ErbB2) Vaccines
c) Her3 (ErbB3) Vaccines

4) Antibodies Targeting the ErbB/Her Receptor Family
a) Selective EGF-R (ErbB1) Antibodies
- Erbitux Pipeline
- Vectibix Pipeline
- Nimotuzumab Pipeline
- Pipeline of Other Selective EGF-R (ErbB1) Antibodies
- Biosimilar Cetuximab Pipeline
- Biosimilar Panitumumab Pipeline

b) Selective Her2 (ErbB2) Antibodies
- Herceptin Pipeline
- Perjeta Pipeline
- Kadcyla Pipeline
- Pipeline of Other Selective Her2 (ErbB2) Antibodies
- Biosimilar Trastuzumab Pipeline
c) Selective Her3 (ErbB3) Antibodies
d) Dual and Pan ErbB / Her Antibodies
e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism

5) Corporate ErbB/Her Receptor Antagonist R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top